Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising results in initial clinical assessments . Ongoing https://bookmarksden.com/story21544357/retatrutide-emerging-studies-and-possible-therapeutic-applications